Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 5Brain Neoplasms 2Neuroblastoma 1Meningioma 1Glioblastoma 1Esthesioneuroblastoma, Olfactory 1

Interventions

Docetaxel 8Radiotherapy 6Filgrastim 5Cisplatin 5Radiotherapy, Intensity-Modulated 3Etoposide 3Erlotinib Hydrochloride 3Chemotherapy, Adjuvant 3Cetuximab 3Capecitabine 3Bevacizumab 3sargramostim 2Peripheral Blood Stem Cell Transplantation 2Paclitaxel 2Gemcitabine 2Cyclophosphamide 2Carboplatin 2Acupuncture Therapy 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tanespimycin 1pentetreotide 1oncogene protein E7, Human papillomavirus type 16 1olaparib 1oblimersen 1lutetium Lu 177 dotatate 1etoposide phosphate 1entinostat 1enasidenib 1cevimeline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esthesioneuroblastoma, Olfactory × apatinib × CNS × Clear all
NCT06308575 2025-01-10

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNS

Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡